The only FDA-approved, wearable cancer treatment device may expand its reach. A Phase III trial of Optune (NovoTTF-100A System) from Novocure was halted early due to statistically significant efficacy for the device in combination with chemotherapy to treat newly diagnosed glioblastoma patients.
More than two dozen top-selling cancer drugs are on a hit list in the U.K. The country's Cancer Drugs Fund, designed to cover oncology meds not approved by cost-effectiveness watchdogs, plans to take a sharp look at these drugs at a meeting next month. And some of them may find themselves shut out for funding--unless new discount plans are in the offing.
Google has dedicated more than 100 employees from multiple disciplines to making its vision of nanotechnology-enabled detection of cancer and other diseases a reality. Any tangible product resulting from this ambitious effort is at least 5 to 7 years away.
Researchers at NC State University and the University of North Carolina have developed a DNA-based delivery vehicle capable of acting as a Trojan horse in cancer cells. Using DNA as a cage instead of synthetic materials makes the vehicle less toxic to healthy cells and allows for the attachment of precise targeting mechanisms.
The list of life science data projects underpinned by Google keeps getting longer. Having signed up to the BRAIN Initiative last week, Google has now teamed up with ISB and SRA International to work on a project for the National Cancer Institute.
The National Cancer Institute has launched a three to four year broad-based study of exceptional responders--patients who have had particularly good outcomes on cancer therapies as compared to their peers. The initiative was first considered a few years ago when it started to become easier to determine the molecular basis of why a particular patient's cancer responds to a molecularly targeted drug, but it is only being undertaken now.
A Purdue University team has created a new chip that promises to help test how cancer-killing nanoparticles react in a tumor environment. Because different nanoparticles perform vastly different functions in drug delivery, it's important to determine early on what kind of effect they will have on a tumor and what it would take to improve their outcome.
Combining chemotherapy and radiotherapy would be ideal for cancer treatment, but administering both at the same time can lead to unacceptable and often deadly levels of toxicity. Now researchers have developed liposomes that contain a chemotherapy drug activated by radiotherapy, offering both cancer-killing power and a targeted approach in a more controlled manner.
ReWalk Robotics, which offers the first robotic exoskeleton for spinal cord injury patients to be cleared by FDA, raised $36 million in an IPO. It didn't wow investors too much--pricing below the anticipated range. Meanwhile, another medical device company stepped into the IPO queue; proton radiation therapy company Mevion Medical Systems filed to raise up to $69 million.
A bioengineering professor says he has developed nanoparticles that can carry cancer-fighting insect toxins directly to tumors, sparing the rest of the body from nasty side effects, including damage to the heart, bleeding underneath the skin and unwanted clotting.